Breaking News Instant updates and real-time market news.

ATRS

Antares Pharma

$3.02 /

+0.045 (+1.52%)

07:33
11/05/20
11/05
07:33
11/05/20
07:33

Antares Pharma reports Q3 EPS 3c, consensus 2c

Reports Q3 revenue $40M, consensus $35.67M. "We are excited to report another quarter of strong financial results that illustrate the significant growth across our diversified business of both proprietary and partner revenue. Our total revenue increased almost 17% year-over-year to $40.0 million, primarily driven by strong demand for XYOSTED and Teva's generic Epipen. XYOSTED continues to represent our biggest growth driver, with 129% quarterly growth and 237% year-to-date growth in total prescriptions compared to the same periods in 2019. We believe the ongoing challenges for patients and physicians due to the pandemic will further support the increased demand for an easy-to-use, painless at-home testosterone replacement therapy. While we also remain committed to the development of our internal pipeline focused on urology and endocrinology, we are excited about the recent U.S. licensing of NOCDURNA which immediately expands our proprietary portfolio offering and leverages our existing salesforce given the significant overlap in urology call points," said Robert F. Apple, President and Chief Executive Officer of Antares Pharma. Furthermore, we have a development pipeline with our partners that we believe are underappreciated opportunities. As generic teriparatide is launched in 11 European countries, Canada and Israel by Teva, we remain eager for the potential U.S approval. We also look forward to Idorsia initiating their Phase 3 trial for the selatogrel pen and being able to provide a timeline for the Pfizer program as we look ahead. Overall, we believe our diversified business will continue to advance and support our future aggressive growth," Mr. Apple concluded.

  • 05

    Nov

ATRS Antares Pharma
$3.02 /

+0.045 (+1.52%)

11/06/19 H.C. Wainwright
Antares reported revenue upside across portfolio, says H.C. Wainwright

TODAY'S FREE FLY STORIES

Recommendations
JPMorgan reiterates Overweight on SmileDirectClub after management meetings » 08:04
11/24/20
11/24
08:04
11/24/20
08:04
SDC

SmileDirectClub

$12.46 /

+1.57 (+14.42%)

JPMorgan analyst Robbie…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

09/17/20 Stifel
SmileDirectClub price target raised to $14 from $11 at Stifel
09/09/20 Wolfe Research
Wolfe Research upgrades SmileDirectClub to Peer Perform as shifts pay off
09/09/20 Wolfe Research
SmileDirectClub upgraded to Peer Perform from Underperform at Wolfe Research
09/03/20 Stifel
SmileDirectClub imminent price increase can create 'solid' tailwind, says Stifel
SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

  • 24
    Nov
  • 19
    Nov
SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

Hot Stocks
Cypress reports metallurgical results from Clayton Valley Lithium Project » 08:03
11/24/20
11/24
08:03
11/24/20
08:03
CYDVF

Cypress Development

$0.00 /

+ (+0.00%)

Cypress Development…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CYDVF Cypress Development
$0.00 /

+ (+0.00%)

Hot Stocks
Medtronic CEO: Company continues to monitor Covid resurgence around the world » 08:03
11/24/20
11/24
08:03
11/24/20
08:03
MDT

Medtronic

$111.08 /

+0.905 (+0.82%)

Comments taken from Q2…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MDT Medtronic
$111.08 /

+0.905 (+0.82%)

MDT Medtronic
$111.08 /

+0.905 (+0.82%)

11/18/20 Wells Fargo
Medtronic price target raised to $127 from $118 at Wells Fargo
11/17/20 Piper Sandler
Boston Scientific recall 'positive' for Edwards, Medtronic, says Piper Sandler
10/28/20 Piper Sandler
CMS proposal on CGMs 'modest positive' for Medtronic, says Piper Sandler
10/16/20 Morgan Stanley
Morgan Stanley positively biased on Medtronic, but awaits execution
MDT Medtronic
$111.08 /

+0.905 (+0.82%)

MDT Medtronic
$111.08 /

+0.905 (+0.82%)

MDT Medtronic
$111.08 /

+0.905 (+0.82%)

MDT Medtronic
$111.08 /

+0.905 (+0.82%)

Hot Stocks
Bally's announces partnership with Elite Casino Resorts » 08:02
11/24/20
11/24
08:02
11/24/20
08:02
BALY

Bally's

$45.75 /

-2.89 (-5.94%)

Bally's announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
BALY Bally's
$45.75 /

-2.89 (-5.94%)

BALY Bally's
$45.75 /

-2.89 (-5.94%)

11/20/20 Truist
Bally's price target raised to $65 from $32 at Truist
11/20/20 Benchmark
Sinclair Broadcast price target raised to $35 from $28 at Benchmark
BALY Bally's
$45.75 /

-2.89 (-5.94%)

Hot Stocks
Patrick Industries appoints Jake Petrovich as CFO » 08:02
11/24/20
11/24
08:02
11/24/20
08:02
PATK

Patrick Industries

$65.92 /

+4.27 (+6.93%)

Patrick Industries…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PATK Patrick Industries
$65.92 /

+4.27 (+6.93%)

PATK Patrick Industries
$65.92 /

+4.27 (+6.93%)

11/23/20 CL King
Patrick Industries' prospects 'never better,' says CL King
09/29/20 Baird
Patrick Industries designated a Fresh Pick at Baird
08/17/20 Wells Fargo
Patrick Industries price target raised to $70 from $55 at Wells Fargo
07/31/20 BofA
Patrick Industries upgraded to Buy from Neutral at BofA
PATK Patrick Industries
$65.92 /

+4.27 (+6.93%)

Hot Stocks
Centro Rossi implements Konica Minolta's Exa Platform across multiple centers » 08:02
11/24/20
11/24
08:02
11/24/20
08:02
KNCAY

Konica Minolta

$0.00 /

+ (+0.00%)

Konica Minolta Healthcare…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
KNCAY Konica Minolta
$0.00 /

+ (+0.00%)

KNCAY Konica Minolta
$0.00 /

+ (+0.00%)

05/05/20 Macquarie
Konica Minolta downgraded to Neutral from Outperform at Macquarie
Earnings
Analog Devices reports Q4 adj, EPS $1.44, consensus $1.32 » 08:02
11/24/20
11/24
08:02
11/24/20
08:02
ADI

Analog Devices

$137.15 /

+2.28 (+1.69%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADI Analog Devices
$137.15 /

+2.28 (+1.69%)

ADI Analog Devices
$137.15 /

+2.28 (+1.69%)

11/18/20 Oppenheimer
Analog Devices price target raised to $155 from $140 at Oppenheimer
11/09/20 Evercore ISI
Analog Devices upgraded to Outperform from In Line at Evercore ISI
10/02/20 Citi
STMicroelectronics preannouncement positive for Texas Instruments, says Citi
09/29/20 KeyBanc
Analog Devices price target lowered to $150 from $155 at KeyBanc
ADI Analog Devices
$137.15 /

+2.28 (+1.69%)

ADI Analog Devices
$137.15 /

+2.28 (+1.69%)

ADI Analog Devices
$137.15 /

+2.28 (+1.69%)

Initiation
Atea Pharmaceuticals initiated with an Overweight at Morgan Stanley » 08:02
11/24/20
11/24
08:02
11/24/20
08:02
AVIR

Atea Pharmaceuticals

$33.39 /

+0.17 (+0.51%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AVIR Atea Pharmaceuticals
$33.39 /

+0.17 (+0.51%)

AVIR Atea Pharmaceuticals
$33.39 /

+0.17 (+0.51%)

08:00 Today JPMorgan
Atea Pharmaceuticals initiated with an Overweight at JPMorgan
06:59 Today William Blair
William Blair starts Atea Pharmaceuticals with Outperform, $60 fair value
06:17 Today William Blair
Atea Pharmaceuticals initiated with an Outperform at William Blair
  • 30
    Oct
Recommendations
Roku price target raised to $310 from $260 at BofA » 08:01
11/24/20
11/24
08:01
11/24/20
08:01
ROKU

Roku

$276.60 /

+13.4 (+5.09%)

BofA analyst Ruplu…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ROKU Roku
$276.60 /

+13.4 (+5.09%)

ROKU Roku
$276.60 /

+13.4 (+5.09%)

11/23/20 Needham
Roku price target raised to $315 from $255 at Needham
11/19/20 Pivotal Research
Pivotal Research upgrades Roku to Hold with lead seeming sustainable
11/19/20 Pivotal Research
Roku upgraded to Hold from Sell at Pivotal Research
11/10/20 Truist
Roku price target raised to $220 from $185 at Truist
ROKU Roku
$276.60 /

+13.4 (+5.09%)

  • 17
    Mar
ROKU Roku
$276.60 /

+13.4 (+5.09%)

ROKU Roku
$276.60 /

+13.4 (+5.09%)

ROKU Roku
$276.60 /

+13.4 (+5.09%)

Initiation
Atea Pharmaceuticals initiated with an Overweight at JPMorgan » 08:00
11/24/20
11/24
08:00
11/24/20
08:00
AVIR

Atea Pharmaceuticals

$33.39 /

+0.17 (+0.51%)

JPMorgan analyst Eric…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AVIR Atea Pharmaceuticals
$33.39 /

+0.17 (+0.51%)

AVIR Atea Pharmaceuticals
$33.39 /

+0.17 (+0.51%)

06:59 Today William Blair
William Blair starts Atea Pharmaceuticals with Outperform, $60 fair value
06:17 Today William Blair
Atea Pharmaceuticals initiated with an Outperform at William Blair
  • 30
    Oct
Options
XPeng call buyer realizes 298% same-day gains » 08:00
11/24/20
11/24
08:00
11/24/20
08:00
XPEV

Xpeng

$72.22 /

+18.37 (+34.11%)

Notable profits for the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XPEV Xpeng
$72.22 /

+18.37 (+34.11%)

XPEV Xpeng
$72.22 /

+18.37 (+34.11%)

11/16/20 Citi
Xpeng price target raised to $57.71 from $34.70 at Citi
11/09/20 JPMorgan
Xpeng price target raised to $43 from $27 at JPMorgan
11/04/20
Fly Intel: Top five analyst initiations
11/04/20 Citi
Xpeng initiated with a Buy at Citi
XPEV Xpeng
$72.22 /

+18.37 (+34.11%)

  • 27
    Aug
XPEV Xpeng
$72.22 /

+18.37 (+34.11%)

XPEV Xpeng
$72.22 /

+18.37 (+34.11%)

Recommendations
Align Technology price target raised to $515 from $432 at Credit Suisse » 07:59
11/24/20
11/24
07:59
11/24/20
07:59
ALGN

Align Technology

$476.56 /

+30.13 (+6.75%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

07:07 Today Goldman Sachs
Align Technology price target raised to $535 from $472 at Goldman Sachs
06:55 Today Baird
Align Technology price target raised to $530 from $450 at Baird
06:26 Today Piper Sandler
Align Technology price target raised to $525 from $500 at Piper Sandler
11/23/20 Piper Sandler
Align Technology price target raised to $525 from $500 at Piper Sandler
ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

Recommendations
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley » 07:58
11/24/20
11/24
07:58
11/24/20
07:58
KYMR

Kymera Therapeutics

$48.05 /

-1.55 (-3.13%)

, NRIX

Nurix Therapeutics

$37.43 /

-0.39 (-1.03%)

, CCCC

C4 Therapeutics

$29.07 /

+0.41 (+1.43%)

, ARVN

Arvinas

$23.34 /

+0.1 (+0.43%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$48.05 /

-1.55 (-3.13%)

NRIX Nurix Therapeutics
$37.43 /

-0.39 (-1.03%)

ARVN Arvinas
$23.34 /

+0.1 (+0.43%)

KYMR Kymera Therapeutics
$48.05 /

-1.55 (-3.13%)

11/13/20 Piper Sandler
Kymera Therapeutics initiated with an Overweight at Piper Sandler
09/15/20 Morgan Stanley
Kymera Therapeutics initiated with an Equal Weight at Morgan Stanley
09/15/20 Cowen
Cowen starts Kymera at Outperform, sees platform positioned for success
09/15/20 Guggenheim
Kymera Therapeutics initiated with a Buy at Guggenheim
NRIX Nurix Therapeutics
$37.43 /

-0.39 (-1.03%)

11/19/20 Baird
Baird starts Nurix Therapeutics with Outperform, $40 price target
11/18/20 Baird
Nurix Therapeutics initiated with an Outperform at Baird
08/18/20
Fly Intel: Top five analyst initiations
08/18/20 JPMorgan
Nurix Therapeutics initiated with an Overweight at JPMorgan
CCCC C4 Therapeutics
$29.07 /

+0.41 (+1.43%)

10/28/20 UBS
C4 Therapeutics initiated with a Buy at UBS
10/27/20 Jefferies
C4 Therapeutics initiated with a Buy at Jefferies
10/27/20 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
ARVN Arvinas
$23.34 /

+0.1 (+0.43%)

10/14/20 Roth Capital
Pipeline expansion showcases Arvinas' PROTACs broad potential, says Roth Capital
06/01/20 Citi
Arvinas upgraded to Buy from Neutral at Citi
05/29/20 Roth Capital
Roth Capital recommends buying Arvinas on ASCO dip
05/29/20 Piper Sandler
Arvinas should be bought on weakness after ASCO update, says Piper Sandler
NRIX Nurix Therapeutics
$37.43 /

-0.39 (-1.03%)

ARVN Arvinas
$23.34 /

+0.1 (+0.43%)

  • 02
    Oct
  • 21
    Aug
  • 24
    Jul
Hot Stocks
Best Buy plans to resume share repurchases during Q4 » 07:57
11/24/20
11/24
07:57
11/24/20
07:57
BBY

Best Buy

$122.08 /

+2.9 (+2.43%)

The company suspended…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BBY Best Buy
$122.08 /

+2.9 (+2.43%)

BBY Best Buy
$122.08 /

+2.9 (+2.43%)

10/29/20 R5 Capital
Best Buy upgraded to Hold from Sell at R5 Capital
10/28/20 Piper Sandler
Piper calls Best Buy a favorite idea after 'very favorable' checks
10/23/20 Oppenheimer
Best Buy downgraded to Perform from Outperform at Oppenheimer
10/23/20 Oppenheimer
Best Buy downgraded to Perform from Outperform at Oppenheimer
BBY Best Buy
$122.08 /

+2.9 (+2.43%)

BBY Best Buy
$122.08 /

+2.9 (+2.43%)

BBY Best Buy
$122.08 /

+2.9 (+2.43%)

BBY Best Buy
$122.08 /

+2.9 (+2.43%)

Recommendations
Chart Industries price target raised to $109 from $92 at Credit Suisse » 07:56
11/24/20
11/24
07:56
11/24/20
07:56
GTLS

Chart Industries

$103.77 /

+3.18 (+3.16%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GTLS Chart Industries
$103.77 /

+3.18 (+3.16%)

GTLS Chart Industries
$103.77 /

+3.18 (+3.16%)

10/27/20 Citi
Chart Industries price target raised to $100 from $90 at Citi
10/23/20 Lake Street
Chart Industries price target raised to $111 from $81 at Lake Street
10/23/20 Craig-Hallum
Chart Industries price target raised to $107 from $85 at Craig-Hallum
10/23/20 Credit Suisse
Chart Industries price target raised to $92 from $80 at Credit Suisse
GTLS Chart Industries
$103.77 /

+3.18 (+3.16%)

Recommendations
Ambarella price target raised to $83 from $79 at Morgan Stanley » 07:52
11/24/20
11/24
07:52
11/24/20
07:52
AMBA

Ambarella

$66.20 /

-0.25 (-0.38%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMBA Ambarella
$66.20 /

-0.25 (-0.38%)

AMBA Ambarella
$66.20 /

-0.25 (-0.38%)

06:55 Today Deutsche Bank
Ambarella price target raised to $60 from $50 at Deutsche Bank
06:49 Today Roth Capital
Ambarella price target raised to $70 from $55 at Roth Capital
11/23/20 Summit Insights
Ambarella upgraded to Buy from Hold at Summit Insights
11/04/20 KeyBanc
KeyBanc lays out possible M&A candidates as semi consolidation heats ups
AMBA Ambarella
$66.20 /

-0.25 (-0.38%)

AMBA Ambarella
$66.20 /

-0.25 (-0.38%)

AMBA Ambarella
$66.20 /

-0.25 (-0.38%)

Recommendations
Nutanix price target raised to $35 from $27 at Wells Fargo » 07:47
11/24/20
11/24
07:47
11/24/20
07:47
NTNX

Nutanix

$28.42 /

-0.07 (-0.25%)

Wells Fargo analyst Aaron…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

07:40 Today Northland
Nutanix price target raised to $38 from $31 at Northland
07:18 Today RBC Capital
Nutanix price target raised to $34 from $29 at RBC Capital
06:28 Today Piper Sandler
Nutanix price target raised to $30 from $26 at Piper Sandler
05:18 Today Goldman Sachs
Nutanix upgraded to Neutral from Sell at Goldman Sachs
NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

Hot Stocks
Goldfield to be acquired by First Reserve for $7.00 per share » 07:46
11/24/20
11/24
07:46
11/24/20
07:46
GV

Goldfield Corp

$4.25 /

-0.02 (-0.47%)

The Goldfield Corporation…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
GV Goldfield Corp
$4.25 /

-0.02 (-0.47%)

Recommendations
Agilent price target raised to $120 from $105 at Wells Fargo » 07:46
11/24/20
11/24
07:46
11/24/20
07:46
A

Agilent

$112.18 /

+1.28 (+1.15%)

Wells Fargo analyst Dan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
A Agilent
$112.18 /

+1.28 (+1.15%)

A Agilent
$112.18 /

+1.28 (+1.15%)

06:52 Today Baird
Agilent price target raised to $118 from $104 at Baird
06:30 Today Citi
Agilent price target raised to $115 from $100 at Citi
11/17/20 Cleveland Research
Agilent upgraded to Buy from Neutral at Cleveland Research
11/09/20 KeyBanc
Agilent initiated with an Overweight at KeyBanc
A Agilent
$112.18 /

+1.28 (+1.15%)

A Agilent
$112.18 /

+1.28 (+1.15%)

A Agilent
$112.18 /

+1.28 (+1.15%)

Syndicate
SmileDirectClub 10M share Block Trade priced at $11.75 » 07:45
11/24/20
11/24
07:45
11/24/20
07:45
SDC

SmileDirectClub

$12.46 /

+1.57 (+14.42%)

The deal range was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

09/17/20 Stifel
SmileDirectClub price target raised to $14 from $11 at Stifel
09/09/20 Wolfe Research
Wolfe Research upgrades SmileDirectClub to Peer Perform as shifts pay off
09/09/20 Wolfe Research
SmileDirectClub upgraded to Peer Perform from Underperform at Wolfe Research
09/03/20 Stifel
SmileDirectClub imminent price increase can create 'solid' tailwind, says Stifel
SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

  • 24
    Nov
  • 19
    Nov
SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

SDC SmileDirectClub
$12.46 /

+1.57 (+14.42%)

General news
Treasury Market Outlook: stocks extended gains overnight » 07:45
11/24/20
11/24
07:45
11/24/20
07:45

Treasury Market Outlook:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Downgrade
Jefferies downgrades Ulta Beauty to Hold after holiday spending survey » 07:43
11/24/20
11/24
07:43
11/24/20
07:43
ULTA

Ulta Beauty

$282.71 /

+8.93 (+3.26%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ULTA Ulta Beauty
$282.71 /

+8.93 (+3.26%)

ULTA Ulta Beauty
$282.71 /

+8.93 (+3.26%)

05:30 Today Jefferies
Ulta Beauty downgraded to Hold from Buy at Jefferies
11/23/20 Oppenheimer
Ulta Beauty price target raised to $305 from $280 at Oppenheimer
11/18/20 R5 Capital
Target upgraded to Buy at R5 Capital following quarterly results
11/18/20 Piper Sandler
Ulta Beauty price target raised to $300 from $288 at Piper Sandler
ULTA Ulta Beauty
$282.71 /

+8.93 (+3.26%)

ULTA Ulta Beauty
$282.71 /

+8.93 (+3.26%)

ULTA Ulta Beauty
$282.71 /

+8.93 (+3.26%)

ULTA Ulta Beauty
$282.71 /

+8.93 (+3.26%)

Hot Stocks
iBio issued U.S. patent covering endostatin peptides for treating fibrosis » 07:41
11/24/20
11/24
07:41
11/24/20
07:41
IBIO

iBio

$1.47 /

-0.13 (-8.13%)

iBio announced that the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IBIO iBio
$1.47 /

-0.13 (-8.13%)

IBIO iBio
$1.47 /

-0.13 (-8.13%)

11/18/20 Alliance Global Partners
iBio price target lowered to $2 from $3.10 at Alliance Global Partners
08/11/20 Alliance Global Partners
iBio price target raised to $6.65 from $2.55 at Alliance Global Partners
06/26/20 Alliance Global Partners
iBio initiated with a Buy at Alliance Global Partners
IBIO iBio
$1.47 /

-0.13 (-8.13%)

IBIO iBio
$1.47 /

-0.13 (-8.13%)

IBIO iBio
$1.47 /

-0.13 (-8.13%)

Hot Stocks
Capricor Therapeutics starts dosing patients in Phase 2 trial of CAP-1002 » 07:40
11/24/20
11/24
07:40
11/24/20
07:40
CAPR

Capricor Therapeutics

$4.17 /

-0.16 (-3.70%)

Capricor Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
CAPR Capricor Therapeutics
$4.17 /

-0.16 (-3.70%)

CAPR Capricor Therapeutics
$4.17 /

-0.16 (-3.70%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
CAPR Capricor Therapeutics
$4.17 /

-0.16 (-3.70%)

CAPR Capricor Therapeutics
$4.17 /

-0.16 (-3.70%)

Recommendations
Nutanix price target raised to $38 from $31 at Northland » 07:40
11/24/20
11/24
07:40
11/24/20
07:40
NTNX

Nutanix

$28.42 /

-0.07 (-0.25%)

Northland analyst Nehal…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

07:18 Today RBC Capital
Nutanix price target raised to $34 from $29 at RBC Capital
06:28 Today Piper Sandler
Nutanix price target raised to $30 from $26 at Piper Sandler
05:18 Today Goldman Sachs
Nutanix upgraded to Neutral from Sell at Goldman Sachs
11/19/20 OTR Global
Nutanix upgraded to Positive from Mixed at OTR Global
NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.